# Executive Production Review

## Decision

The project is a strong production-oriented portfolio reference implementation. It is suitable for merge after all validation gates pass, but it must not be represented as a clinically deployed or clinically validated system.

## Strengths

- Integrated predictive and causal decision intelligence
- Explicit clinical safety boundary
- Typed and authenticated API
- Explainability, fairness, calibration, and drift capabilities
- FHIR-style interoperability and clinician feedback
- MLflow, Prometheus/Grafana, Docker, Kubernetes, and CI scaffolding

## Remaining limitations

- Synthetic data and demonstration model artifacts
- No prospective or clinical validation
- Local JSONL feedback persistence
- Raw identifiers remain possible unless upstream de-identification is enforced
- FHIR adapter is not a certified EHR integration
- Kubernetes and managed feature-store paths require environment-specific implementation
- No regulatory, privacy, security, or hospital operational approval

## Merge recommendation

Merge only when tests, CI, Docker smoke testing, repository hygiene, API/OpenAPI consistency, and documentation verification all pass.
